1. Scrip
  2. >>New Products

Biogen Sees Improving Momentum In Slow Leqembi Launch

CEO Viehbacher ‘Encouraged’ By Prescriber Growth

 
• By Mandy Jackson

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Q1 First Quarter Budget Speedometer 3d Render Illustration
Biogen's New Launches Revved Up In Q1 • Source: Shutterstock

Biogen, Inc. CEO Christopher Viehbacher acknowledged the longstanding challenge to deliver financial growth right at the beginning of the company’s first quarter earnings call on 24 April, before he and his executive team presented evidence that new product launches – Leqembi (lecanemab) for Alzheimer’s disease, the Friedreich’s ataxia drug Skyclarys (omaveloxolone) and the postpartum depression drug Zurzuvae (zuranolone) – may soon reverse their revenue fortunes. 

First quarter total revenue decreased 7% year-over-year to $2.29bn, just below analyst consensus of $2.31bn, but non-GAAP earnings per share...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

 
• By Alaric DeArment

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Pipeline Watch: Five Approvals And Twelve Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 
• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

GSK’s Blenrep US Setback Could Go From Bad To Worse

 
• By Sushmita Panda

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.